Business Information
The group's principal activities are to discover, develop, manufacture and market pharmaceutical-based health care solutions. The pharmaceutical products include: neuroscience, endocrine, anti-infective, cardiovascular agents, oncology and animal health. The group specializes in research and development, production and marketing of products for the treatment of diabetes worldwide, such as insulin and insulin delivery devices. The group's pharmaceutical products are distributed through wholesalers that serve physicians, pharmacies, hospitals and other health care professionals. The group's patents include zyprexa, prozac, permax, darvon, humulin, evista, humalog, actos, humatrope, ceclor, vancocin, keflex, nebcin , lorabid, gemzar, tylan, rumensin, micotil, surmax, coban, reopro, xigris, dobutrex and axid. On 12- feb-2004, the group acquired applied molecular evolution inc. It operates in the United States, western Europe and other foreign countries.
|
|
Name |
Title
|
Email
|
| Sidney Taurel | Chmn., CEO | N/A | | Bryce Carmine | Pres. - Global Brand Development Teams | N/A | | Deirdre Connelly | Pres. - Lilly USA | N/A | | Frank Deane | Pres. - Manufacturing | N/A | | Jacques Tapiero | Pres. - Intercontinental Operations | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 15,691,000 | 2,662,700 | | 2005 | 14,645,300 | 1,979,600 | | 2004 | 13,857,900 | 1,810,100
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
